Characterization of Variations in PB2, NS1, M, Neuraminidase and Hemagglutinin of Influenza A (H3N2) Viruses in Iran

Jila Yavarian 1, Nazanin Zahra Shafiei Jandaghi 1, Maryam Naseri 1, Talat Mokhtari Azad 1,*

1Virology Department, School of Public Health, Tehran University of Medical Sciences
*

Corresponding author: Talat Mokhtari Azad, Tehran University of Medical Sciences, Porsina Ave, Keshavarz Blvd, Tehran, IR Iran. Tel: +98-2188962343, Fax: +98-2188962343, E-mail: nljy575@yahoo.com, mokhtari@sina.tums.ac.ir

Received: November 11, 2012; Revised: January 28, 2013; Accepted: March 3, 2013

1. Background

Influenza viruses have segmented genome composed of eight single-stranded negative-sense RNAs, encoding 10-11 proteins. Hemagglutinin (HA), PB2 and NS1 are known as major determinants of the host range restriction and pathogenicity of influenza viruses. Neuraminidase (NA) and M genes also play a role in the pathogenesis. HA and NA are two envelope proteins involved in the virus virulence (1). HA plays a role in binding and uptake of the virus into the cells. It is synthesized as a single polypeptide chain (HA0) which gets cleaved by cellular proteases and is essential for the virus infectivity (2). The sequence of HA cleavage site is important in the pathogenicity, since highly-pathogenic H5 and H7 viruses contain multiple basic amino acids in this site, which are recognized by ubiquitous proteases, furin, and PC6. In contrast, avirulent viruses, except for H7N7 equine influenza viruses (3), contain a single arginine residue at the HA cleavage site and are cleaved in only a few organs (4). Receptor-binding specificity of HA is accountable for the host range restriction of influenza viruses (5). Amino acids of the receptor-binding pocket are important in the receptor specificity (6).

The influenza virulence and host range are also affected by the number of oligosaccharide side chains. HAs typically contain five to 11 glycosylation sites that affect the receptor-binding affinity and/or specificity, antigenicity, virulence, and host range (7-9). These carbohydrates are significant for interaction of HA and NA, where an equilibrium is required between the receptor binding activity and virus release (10-12). NA removes the sialic acid from HA of the newly-synthesized virus particles and helps in release of the virus from the infected cells. To act properly, NA must share the specificity with HA. Amino acid substitutions in and around the active site may be important in the specificity of NA (13-15).

NS1 is an interferon (IFN) antagonist that allows efficient virus replication. NS1 proteins may differ among viruses regarding their ability to counteract the cellular IFN system and thereby affect the viral pathogenicity (16). PB2 protein is a component of the viral replication complex, recognized as an important determinant of virulence and host range restriction (17).

1. Implication for health policy/practice/research/medical education:

Identification of the alterations in genes responsible for virus virulence and pathogenicity important for preparing the best methods for virus prevention and treatment.
matrix protein. Mutations in this protein are related to growth, host range, and virulent phenotypes. Capacity of influenza A viruses to replicate in the allantoic sac of the chicken embryo has been attributed to the M gene (18).

2. Objectives
The ultimate goal of this study was to determine the variations of viral genes associated with virulence and pathogenesis of some influenza A (H3N2) viruses in Iran.

3. Materials and Methods

3.1. Virus Detection and Isolation
Throat swab specimens from 432 patients with influenza-like illnesses (fever, cough and sore throat) were referred to the National Influenza Centre at the School of Public Health, Tehran University of Medical Sciences, Tehran, Iran. Virus-positive samples were identified by real-time PCR and inoculated into Madin-Darby canine kidney (MDCK) cells for further virus isolation.

3.2. RNA Extraction and RT-PCR
RNAs from positive A (H3N2) samples were extracted using a QIAGEN viral RNA Mini Kit (Cat. No. 52906, Germany) at WHO Influenza Centre, National Institute for Medical Research, London. RT-PCR was performed with a QIAGEN One-Step RT-PCR Kit (Cat. No. 210212, Germany) using primers for HA, M, PB2, NS, and NA genes provided by WHO Influenza Centre, National Institute for Medical Research, London. Primer sequences are available upon request. One-Step RT-PCR was performed with cDNA synthesis (60°C for 1 minute, 50°C for 30 minutes and 95°C for 15 minutes), DNA amplification (94°C for 30 seconds, 50°C for 30 seconds and 72°C for 1 minute) for 40 cycles and final extension at 72°C for 10 minutes. Desirable products were obtained for all genes except for M gene, which seven samples were positive and seven were negative. Afterwards, hemi-nested RT-PCR was performed on negative samples with Platinum-PFX enzyme; the PCR program was: denaturation at 95°C for 5 minutes, primer annealing at 55°C for 30 seconds, extension at 72°C for 1 minute in 40 amplification cycles, and a 10 minutes of final extension at 68°C. PCR product lengths were as follows: PB2: 550 base pair (bp), NS: 850 bp, M: 950 bp; NA and HA in two parts: HA: 850 bp and 900 bp, NA: 700 bp and 750 bp. Purification was performed with GFX PCR DNA and Gel Bond Purification Kits (Illustra, 28-9034-71, UK).

3.3. Sequencing
BigDye Terminator V1.1 Cycle Sequencing Kit (Cat. No. 4337449, USA) was used for performing the sequencing reactions with the following program: 25 cycles of 30 seconds denaturation at 96°C, 15 seconds primer annealing at 50°C, and 4 minutes extension at 60°C. After ethanol precipitation, MegaBACE 1000 DNA sequencer was used for resolving the reactions. Wisconsin Sequence Analysis package (GCG), version 10, was used for editing and analyzing the sequences. All the obtained sequences were submitted to the GenBank database under Acc. Nos. FJ664618 to FJ664632 and FJ769856-FJ769915.

4. Results and Discussion
In 14 A/H3N2 viruses, changes in HA, NA, M, NS, and PB2 genes were analyzed in a three-year study. Affinity of the viral HA protein for the host sialic acid receptor is a major determinant of host range. In general, human influenza viruses preferentially interact with SAα2, 6Gal, whereas avian viruses mostly bind to SAα2, 3Gal. In H3 subtype viruses, a glutamine at position 226 and a glycine at position 228 within the receptor-binding pocket of HA preferentially accommodate the 2,3-linked sialic acid, whereas a leucine or isoleucine and a serine at these positions confer SAα2,6Gal specificity (6, 19). In this study, isolates had mutations in the receptor-binding site (Ile226, Pro227, Ser228, and Asp190) of HA that bound to the sialic acid in human cells. Significance of HA cleavability for the pathogenicity of influenza viruses is underscored by the finding that acquisition of a highly-cleavable HA, converts avirulent strains to virulent ones. HA proteins of highly-pathogenic viruses have multiple basic amino acids at the cleavage site, identified by ubiquitous proteases. In contrast, HA proteins of avirulent viruses contain a single arginine residue at the HA cleavage site (as found in this study), cleaved in only a few organs and therefore produce localized infections of respiratory and/or intestinal tract, which are usually asymptomatic or mild (3, 4). HA cleavage efficiency can also be affected by the nature of amino acids downstream of the cleavage site (Pt). Horimoto and Kawaoka showed that HA cleavage by subtilisin-like proteases is influenced by the downstream Pi amino acid in the absence of upstream Pi sequence alterations. Substitution of glycine with isoleucine, leucine, valine or proline resulted in reduction of HA cleavage by endogenous endoproteases (20) as all specimens in this study had glycine downstream of Pt.

Vigerust et al. showed that glycosylation impacts the disease severity as well as the outcome of infection, as N-linked glycosylation attenuates A/H3N2 influenza viruses (1). Some studies have shown that N-linked glycosylation at residues 154-156 in the HA1 region of the HA molecule is important in the H5N1 pathogenesis and low pathogenic viruses do not possess N-linked glycosylation in this site; however, there were some controversial results showing that presence or absence of this glycosylation site alone could not account for the differences in pathogenicity (21, 22). Chen et al. declared that absence of a glycosylation site at amino acid 154 in the HA gene of H5N1 influenza virus was important in virulence determination (23). Pattern of N-linked glycosylation site in this...
study was consistent with the low pathogenicity profile in which there were 11-12 N-linked glycosylation sites and no N-linked glycosylation at residues 154-156. Fujimoto et al. explained the generic profile of influenza A/H3N2 viruses identified in CSF of patients with encephalopathy, showing a substitution, Thr137Phe, involved in the HA receptor binding site. However, more researches are required to confirm that this mutation can actually influence the pathogenicity (24). This substitution was not found in our study.

Smeenk and Brown showed that replacement of a glycin with tryptophan at amino acid 47 of HA2 subunit results in increased virulence (25), although isolates of the present study did not show this change. Isolates of this study did not have Ser227Asp in the HA1, found in A/Hong Kong/213/03 (H5N1) presumably altering the virulence of human H5N1/97 virus in mice (26, 27). Residues 226, 186, and 196 of HA1 are important in the growth of virus in embryonated eggs. Ala196Thr, Val226Ile and Gly81Val increase the growth of virus in these eggs. In the isolates of the present study Val226Ile was found, but these viruses did not grow in the embryonated eggs. Studies showed that Val226Ile, Thr155 and Hist56 existing in these isolates, prevent the growth of virus in the eggs.

NA, similar to HA, influences the host range. Studies have shown that the NA gene of influenza A/WSN/33 virus is associated with neurovirulence in mice and growth in MDBK cells. Nucleotide sequence analysis has shown that no conserved glycosylation site is present at the position 146 of NA of WSN virus, playing an important role in the neurovirulence of WSN virus in mice (28-30). Some other studies have shown that low-pathogen H5N1 viruses have a threonine at residue 222 of N2 NA, creating a potential glycosylation site (N-X-T) in the enzyme active site (31, 32). Goto and Kawaoka revealed that lack of this glycosylation along with presence of a carboxyl-terminal lysine, and not glutamic acid, at this position facilitates efficient virus replication at 37˚C (the body temperature of mammals). In addition, specific adaptation of the viral polymerase to the mammalian host facilitates the transmission of influenza viruses raised in different species; thus, one viral feature is changing the virus to a pandemic strain (17). We found lysine at position 627 and aspartic acid at position 701 of PB2.

Capacities of influenza A viruses to replicate in the allantoic sac of chicken embryo have been attributed to the M gene (18). All high-yield phenotypes contained threonine in position 218 instead of alanine or valine, present in the low-yield phenotypes. However, four amino acid replacements in the M2 gene, i.e. Ile28Val, Arg54Phe (Leu), Tyr57His, and Gly89Ser were found in the high-yield phenotypes. In this study, isolates showed characteristics of the low-yield viruses: in the M1 gene, at residues 15, 218 and 139, all isolates had valine, alanine and threonine, respectively; in the M2 gene, Val28, Leu54, His57 and Ser89 were found.

Katz et al. showed that amino acids isoleucine or threonine at residue 222 of NA, and isoleucine or valine at residue 15 of M1 protein, were related to high and low pathogenicity, respectively (32). Meanwhile, a single amino acid replacement of threonine with alanine in position 139 of the M1 gene leads to an increased growth and virulence (35). In the present study, val15 and thr139 in M1 showed association with low pathogenicity, but I222 in NA conferred high pathogenicity. Despite all these progresses, factors behind the pathogenicity of some human virus subtypes have not been completely determined and a variety of factors might contribute to their pathogenicity. Although the relatively-small sample size restricted our power of analysis, according to our findings, different mutations in genes are responsible for the pathogenesis. We conclude that all of these isolates can grow efficiently in human respiratory cells, but they are not virulent enough to cause a systemic infection. We suggest performing more researches in this regard, especially on animal models.

Acknowledgements
We would like to express our gratitude to all the staff of WHO Influenza Centre, National Institute for Medical Research, Virology Department, Mill Hill, London, and also to the entire staff of National Influenza centre, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran.
Authors’ Contribution
Jila Yavarian: performing the tests and drafting the manuscript. Nazanin Zahra Shafei Jandaghi: RNA extraction. Maryam Naseri: real time-PCR. Talat Mokhtari Azad: supervision.

Financial Disclosure
None declared.

Funding/Support
This research did not receive any financial support.

References
1. Viguerst D, Ulett KB, Boyd KL, Madsen J, Hawgood S, McCullers JA. N-linked glycosylation attenuates H5N2 influenza viruses. J Virol. 2007;81(6):6593–600.
2. Klenk HD, Rott R, Orlich M, Blodorn J. Activation of influenza A viruses by trypsin treatment. Virology. 1976;68(2):426–39.
3. Kawaoka Y. Equine H7N7 influenza A viruses are highly pathogenic in mice without adaptation: potential use as an animal model. J Virol. 1991;65(3):3891–4.
4. Bosch FX, Orlich M, Klenk HD, Rott R. The structure of the hemagglutinin, a determinant for the pathogenicity of influenza viruses. Virology. 1979;99(3):297–207.
5. Glaser I, Stevens J, Zamarin D, Wilson IA, Garcia-Sastre A, Tumpey TM, et al. A single amino acid substitution in 1918 influenza virus hemagglutinin changes receptor binding specificity. J Virol. 2005;79(11):15333–6.
6. Conner RJ, Kawaoka Y, Webster RG, Paulson JC. Receptor specificity in human, avian, and equine H2 and H3 influenza virus isolates. Virology. 1994;205(2):127–21.
7. Gambaryan AS, Marimina VP, Tuzikov AB, Bovin NV, Rudneva IA, Siritsyn BV, et al. Effects of host-dependent glycosylation of hemagglutinin on receptor-binding properties on H5N1 human influenza A virus grown in MDCK cells and in embryonated eggs. Virology. 1998;247(2):370–7.
8. Matrosovich M, Zhou N, Kawaoka Y, Webster R. The surface glyco-proteins of H5 influenza viruses isolated from humans, chickens, and wild aquatic birds have distinguishable properties. J Virol. 1999;73(2):1345–55.
9. Ohuchi M, Ohuchi R, Feldmann A, Klenk HD. Regulation of receptor binding affinity of influenza virus hemagglutinin by its carbohydrates moieties. J Virol. 1997;71(8):4377–84.
10. Klenk HD, Wagner R, Heuer D, Wolff T. Importance of hemagglutinin glycosylation for the biological functions of influenza virus. Virol. 2002;282(1):1–7.
11. Seidel W, Kunell F, Geisler B, Garten W, Herrmann B, Dohner L, et al. Intraepidemic variants of influenza virus H3 hemagglutinin differing in the number of carbohydrate side chains. Arch Virol. 1993;120(1–4):289–96.
12. Wiley DC, Wilson IA, Skehel JJ. Structural identification of the antibody-binding sites of Hong Kong influenza haemagglutinin and their involvement in antigenic variation. Nature. 1988;335(6189):373–8.
13. Kobasa D, Kodihalli S, Luo M, Castrucci MR, Donatelli I, Suzuki Y, et al. Amino acid residues contributing to the substrate specificity of the influenza A virus neuraminidase. J Virol. 1999;73(6):4743–51.
14. Yavarian J, Mokhtari-Azad T, Nadji SA, Zeraati H, Naseri M. Analysis of the hemagglutinin and neuraminidase genes of human influenza A/H3N2 viruses circulating in Iran between 2005 and 2007: antigenic and phylogenetic relationships to vaccine strains. Inter. Virology. 2010;55(2):131–40.
15. Zambon MC. The pathogenesis of influenza in humans. Rev Med Virol. 2001;11(4):227–41.
16. Neumann G, Kawaoka Y. Host range restriction and pathoge-
nicity in the context of influenza pandemic. Emerg Infect Dis. 2005;12(6):981–6.
17. Steel J, Lowen AC, Mubareka S, Palese P. Transmission of influenza virus in a mammalian host is increased by PB2 amino acids 627K or 627E/701N. PLoS Pathog. 2009;5(1).
18. Klimov AI, Sokolov NI, Orlova NG, Gunzburg WV. Correlation of amino acid residues in the M1 and M2 proteins of influenza virus with high yielding properties. Virus Res. 1999;59(1):205–14.
19. Rogers GN, Paulson JC, Daniels RS, Skehel JJ, Wilson IA, Wiley DC. Single amino acid substitutions in influenza haemagglutinin change receptor binding specificity. Nature. 1983;304(5927):76–8.
20. Horimoto T, Kawaoka Y. The hemagglutinin cleavability of a virulent avian influenza virus by subtilisin-like endopeptidases is influenced by the amino acid immediately downstream of the cleavage site. Virology. 1995;210(2):446–70.
21. Bender C, Hall H, Huang J, Klimov A, Cox N, Hay A, et al. Characterization of the surface proteins of influenza A (H5N1) viruses isolated from humans in 1997–98. Virology. 1999;254(2):235–53.
22. Suarez DL, Perdue ML, Cox N, Rowe T, Bender C, Huang J, et al. Comparisons of highly virulent H5N1 influenza A viruses isolated from humans and chickens from Hong Kong. J Virol. 1998;72(5):6768–88.
23. Chen H, Bright RA, Subbarao K, Smith C, Cox N, Katz J, et al. Poly- genetic viruses. Factors involved in pathogenesis of 1997 Hong Kong H5N1 influenza viruses in mice. Virology. 2007;328(2):1259–63.
24. Fujimoto S, Kobayashi M, Uemura O, Iwasa M, Ando T, Kato H, et al. PCR on cerebrospinal fluid to show influenza-associated acute encephalopathy or encephalitis. Lancet. 1993;342(8897):383–5.
25. Smeenk CA, Brown EG. The influenza virus variant A/MX/60-MA possesses single amino acid replacements in the hemagglutinin, controlling virulence, and in the matrix protein, controlling virulence as well as growth. J Virol. 2004;78(5):310–4.
26. Guan Y, Poon LL, Cheung CY, Ellis TM, Lim W, Lipatov AS, et al. H5N1 influenza: a protean pandemic threat. Proc Natl Acad Sci U S A. 2004;101(21):7815–6.
27. Hatta M, Gao P, Halfmann P, Kawaoka Y. Molecular basis for high virulence of Hong Kong H5N1 influenza A viruses. Science. 2001;293(5529):1860–2.
28. Colman PM, Ward CW. Structure and diversity of influenza virus neuraminidase. Curr Top Microbiol Immunol. 1995;191(1):177–205.
29. Lentz MR, Webster RG, Air GM. Site-directed mutation of the active site of influenza neuraminidase and implications for the catalytic mechanism. Biochemistry. 1987;26(17):3535–8.
30. Li S, Schulman J, Ramura S, Palese P. Glycosylation of neuraminidase mediates the neurovirulence of influenza A/H5N1/33 virus. J Virol. 1993;67(9):6667–73.
31. Colman PM, Varghese LN, Laver WG. Structure of the catalytic and antigenic sites in influenza virus neuraminidase. Nature. 1983;303(5912):341–4.
32. Katz JM, Lu X, Tumpey TM, Smith CB, Shaw MW, Subbarao K. Molecular correlates of influenza A H5N1 virus pathogenesis in mice. J Virol. 2007;81(24):10807–10.
33. Goto H, Kawaoka Y. A novel mechanism for the acquisition of virulence by a human influenza A virus. Proc Natl Acad Sci U S A. 1998;95(7):4022–8.
34. Seo SH, Hoffmann E, Webster RG. Lethal H5N1 influenza viruses escape host anti-viral cytokine responses. Nat Med. 2002;8(9):950–4.
35. Seo SH, Hoffmann E, Webster RG. The NS gene of H5N1 influenza viruses circumvents the host anti-viral cytokine responses. Virus Res. 2004;103(1–2):107–13.
36. Li Z, Jiang X, Jiao P, Wang A, Zhao F, Tian G, et al. The NS gene contributes to the virulence of H5N1 avian influenza viruses. J Virol. 2005;79(23):11515–21.
37. Crescenzo-Chaigne B, van der Wel S, Nafakh N. Differential effect of nucleotide substitutions in the 3' arm of the influenza A virus RNA promoter on transcription/replication by avian and human polymerase complexes is related to the nature of PB2 amino acid 627. Virology. 2002;303(2):240–52.
38. Subbarao EK, London W, Murphy BR. A single amino acid in the PB2 gene of influenza A Virus is a determinant of host range. J Virol. 1993;67(4):1761–4.